Can-Fite BioPharma (CANF) EBIT (QoQ) (2014 - 2023)
Can-Fite BioPharma (CANF) EBIT (QoQ) (2014 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.66% |
| Sep 30, 2023 | -4.54% |
| Jun 30, 2023 | 34.22% |
| Mar 31, 2023 | -129.44% |
| Dec 31, 2022 | 54.06% |
| Sep 30, 2022 | -24.30% |
| Jun 30, 2022 | 12.66% |
| Mar 31, 2022 | 41.16% |
| Dec 31, 2021 | -14.76% |
| Sep 30, 2021 | -12.03% |
| Jun 30, 2021 | -44.31% |
| Mar 31, 2021 | 38.90% |
| Dec 31, 2020 | -43.32% |
| Sep 30, 2020 | 35.29% |
| Jun 30, 2020 | 10.41% |
| Mar 31, 2020 | 7.27% |
| Dec 31, 2019 | -65.21% |
| Sep 30, 2019 | 55.81% |
| Jun 30, 2019 | -469.14% |
| Mar 31, 2019 | 168.36% |